Wegovy semaglutide Ozempic is FDA-approved for type 2 diabetes treatment, but may be prescribed off-label for weight loss at a healthcare providers discretion
The compounded version prescribed through Maximus contains the same active molecule but is produced by a compounding pharmacy rather than the original manufacturer, Novo Nordisk
GLP-1 was initially discovered for its ability to enhance glucose-stimulated insulin secretion (GSIS) (Kreymann et al., 1987
A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction
Factors such as not achieving your goal weight loss, having side effects you can't tolerate, or experiencing rare but serious medication reactions are reasons to stop taking the medicine
